BiondVax Pharmaceuticals Ltd. (BVXV)
Stock analysis · NASDAQ · Healthcare · Biotechnology
BiondVax Pharmaceuticals Ltd. (BVXV) is a publicly traded company in the Healthcare sector. Latest price: $1.36. Market cap $4.97M. Trailing PE -21.36. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Earnings
Proprietary Signals
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals Ltd. is an Israeli-based biopharmaceutical company currently in its development stage. Its core mission involves the research, production, and market introduction of therapeutic products designed for the prevention and treatment of a range of infectious and other medical conditions. The company has established strategic licensing and collaboration agreements with prominent scientific institutions, notably the Max Planck Society and the University Medical Center Göttingen. These partnerships are geared towards the advancement and commercialization of nanosized antibodies (NanoAbs), including a specific candidate for COVID-19, and extending this technology to address various other disease indications. Founded in 2003, BiondVax maintains its corporate headquarters in Jerusalem, Israel.
Valuation
| P/E (TTM) | -21.36× |
|---|---|
| P/S (TTM) | 0.00× |
| P/B | -6.29× |
| P/FCF (TTM) | -1.93× |
| EV / EBITDA | -2.20× |
| EV / Sales | 0.00× |
| Earnings Yield | -4.80% |
| Free Cash Flow Yield | -51.93% |
Fundamentals
| Enterprise Value | $23.07M |
|---|---|
| Net Income (TTM) | -$748.43K |
| Free Cash Flow (TTM) | -$8.10M |
| Net Debt | $7.47M |
| Working Capital | $12.03M |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -4.92% |
| Return on Invested Capital | -4.04% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap